#ASCO18: A Weekend of Surprises

Surprising and market-moving information often comes out of the annual American Society of Clinical Oncologists (ASCO) meeting, and so far, ASCO18 hasn't disappointed. From bluebird bio's (NASDAQ:BLUE) great-but-not-good-enough results in multiple myeloma to Loxo Oncology's (NASDAQ:LOXO) stellar results in RET-fusion cancers to Nektar Therapeutics(NASDAQ:NKTR) head-scratching data, here are some quick takes on the data released this weekend.